Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic rece…
Biotechnology
US, Boston [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Karuna Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2021 | -2.5900 | -5.728 | 0 | 5 | -68 | -143 | -68 | -142 | -71 | -143 | 28 | 0 |
| 2022 | -4.9400 | -8.757 | 36 | 4 | -143 | -323 | -143 | 0.96 | -144 | 0.96 | 52 | 0 |
| 2023 | -8.7400 | -11.379 | 10 | 1 | -276 | -433 | -289 | 0.30 | -290 | 0.30 | 76 | 0 |
| 2024 | - | -11.511 | - | 56 | - | -444 | - | -11 | - | -11 | - | 0 |
| 2025 | - | -7.535 | - | 267 | - | -331 | - | -53 | - | -53 | - | 0 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |